TED Tech TED Tech

Can Ozempic end addiction? | Dhruv Khullar | Your Body on Tech

Oct 9, 2026 · 47m

Summary

In this TED Tech episode, host Manoush Zomorodi introduces a special series on how technology reshapes human biology, featuring physician Dhruv Kular. Kular discusses the emerging science of GLP-1 medications, explaining how they act as "moderation molecules" that blunt dopamine spikes to treat addictions like alcoholism and gambling. The conversation explores the neurobiological basis of addiction, the potential for these drugs to reduce stigma, and the ethical challenges of using powerful medical interventions to combat modern excess and distraction.

Topics discussed

Introduction to the TED Tech series and show Preview of Dhruv Kular's talk on GLP-1s and addiction Sponsor segments for Schwab, Rolex, and LA28 Case study: Mary's experience with Ozempic and alcohol History of GLP-1 discovery via Komodo dragon venom Research on GLP-1s and various addiction types Mechanism: Dopamine modulation and reward pathways Limitations: Tolerance and the need for moderation The unpredictability of medical innovation Aristotle's moderation in the age of digital distraction Personal anecdotes from emergency room medicine Sponsor segment for Parloa AI Interview: Mary's weight loss and sobriety maintenance Interview: Evidence for GLP-1s in addiction treatment Interview: The role of dopamine and brain mysteries Interview: Gut-brain axis and receptor distribution Sponsor segments for Creighton and Perk Interview: Shifting blame from character to biology Interview: Broad health benefits beyond weight loss Interview: Adherence, cost, and side effects Interview: Muscle preservation and long-term safety Interview: Preventive use in children and adolescents Interview: Addressing root causes of health epidemics Interview: Unregulated use and cultural phenomena Interview: Future medication options and medicine as tech Interview: Patient autonomy and the need for evidence Interview: The changing patient-physician relationship Interview: The high failure rate of drug development Interview: Personal agency and environmental harmony Interview: Final advice on cautious use Host reflection on skepticism and the peptide craze Credits and preview of the next episode Closing remarks and sponsor segment for Perk Sponsor segment for ServiceNow
Listen ad-free on Castria